1h Free Analyst Time
The Antibody Drug Conjugates Contract Manufacturing Market size was estimated at USD 11.88 billion in 2023, USD 13.06 billion in 2024, and is expected to grow at a CAGR of 11.82% to reach USD 25.99 billion by 2030. Speak directly to the analyst to clarify any post sales queries you may have.
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Antibody Drug Conjugates Contract Manufacturing Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Antibody Drug Conjugates Contract Manufacturing Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.Key Company Profiles
The report delves into recent significant developments in the Antibody Drug Conjugates Contract Manufacturing Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., ADC Therapeutics SA., AstraZeneca PLC, Aurigene Pharmaceutical Services Ltd. by Dr. Reddy's Laboratories, Axplora, Catalent, Inc., Creative Biolabs, Daiichi Sankyo, EirGenix, Inc., Gilead Sciences, GlaxoSmithKline PLC, ImmunoGen, Inc., Merck KgaA, Mersana Therapeutics, MicroBiopharm Japan Co., Ltd., Pfizer Inc., Pierre Fabre S.A, Piramal Pharma Solutions, Recipharm AB, Regeneron Pharmaceuticals, Inc., Samsung Biologics, Sanofi, and Sartorius AG.Market Segmentation & Coverage
This research report categorizes the Antibody Drug Conjugates Contract Manufacturing Market to forecast the revenues and analyze trends in each of the following sub-markets:- Linker
- Cleavable
- Non-cleavable
- Condition
- Breast Cancer
- Lymphoma
- Myeloma
- End Use
- Clinical Trial
- Myeloma Treatment
- Region
- Americas
- Argentina
- Brazil
- Canada
- Mexico
- United States
- California
- Florida
- Illinois
- New York
- Ohio
- Pennsylvania
- Texas
- Asia-Pacific
- Australia
- China
- India
- Indonesia
- Japan
- Malaysia
- Philippines
- Singapore
- South Korea
- Taiwan
- Thailand
- Vietnam
- Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom
- Americas
The report offers valuable insights on the following aspects
- Market Penetration: It presents comprehensive information on the market provided by key players.
- Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
- Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
- Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
- Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
The report addresses key questions such as
- What is the market size and forecast of the Antibody Drug Conjugates Contract Manufacturing Market?
- Which products, segments, applications, and areas should one consider investing in over the forecast period in the Antibody Drug Conjugates Contract Manufacturing Market?
- What are the technology trends and regulatory frameworks in the Antibody Drug Conjugates Contract Manufacturing Market?
- What is the market share of the leading vendors in the Antibody Drug Conjugates Contract Manufacturing Market?
- Which modes and strategic moves are suitable for entering the Antibody Drug Conjugates Contract Manufacturing Market?
Additional Product Information:
- Purchase of this report includes 1 year online access with quarterly updates
- This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website
Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report
Purchase of this report includes 1 year online access with quarterly updates
Table of Contents
1. Preface
2. Research Methodology
4. Market Overview
5. Market Insights
6. Antibody Drug Conjugates Contract Manufacturing Market, by Linker
7. Antibody Drug Conjugates Contract Manufacturing Market, by Condition
8. Antibody Drug Conjugates Contract Manufacturing Market, by End Use
9. Americas Antibody Drug Conjugates Contract Manufacturing Market
10. Asia-Pacific Antibody Drug Conjugates Contract Manufacturing Market
11. Europe, Middle East & Africa Antibody Drug Conjugates Contract Manufacturing Market
12. Competitive Landscape
13. Competitive Portfolio
14. Appendix
List of Figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AbbVie Inc.
- ADC Therapeutics SA.
- AstraZeneca PLC
- Aurigene Pharmaceutical Services Ltd. by Dr. Reddy's Laboratories
- Axplora
- Catalent, Inc.
- Creative Biolabs
- Daiichi Sankyo
- EirGenix, Inc.
- Gilead Sciences
- GlaxoSmithKline PLC
- ImmunoGen, Inc.
- Merck KgaA
- Mersana Therapeutics
- MicroBiopharm Japan Co., Ltd.
- Pfizer Inc.
- Pierre Fabre S.A
- Piramal Pharma Solutions
- Recipharm AB
- Regeneron Pharmaceuticals, Inc.
- Samsung Biologics
- Sanofi
- Sartorius AG
Methodology
LOADING...
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 193 |
Published | March 2024 |
Forecast Period | 2024 - 2030 |
Estimated Market Value ( USD | $ 13.06 Billion |
Forecasted Market Value ( USD | $ 25.99 Billion |
Compound Annual Growth Rate | 11.8% |
Regions Covered | Global |